Transactions

Transactions

  • Avita intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, to fund the marketing and sales effort to support U.S. market launch of the RECELL System
  • Rocket Pharmaceuticals intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, to fund the continued development of the pipeline of gene therapies for rare diseases, enhancements to in-house manufacturing efforts, potential in-license, acquisition or investment in complementary businesses or products, and intends to use the remainder for general working capital and administrative purposes.
  • Acadia intends to use the net proceeds of this offering to fund ongoing commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin and trofinetide, and for general corporate purposes, including working capital.
  • Contango intends to use the net proceeds from the equity follow-on offering to: pay down the current RBL, and for general corporate purposes, including to fund accretive future acquisitions.
  • Use of funds are primarily for pre-production, testing and certification of Nikola Two Alpha & Beta prototypes, development and validation of manufacturing processes.
  • Sarepta intends to use the net proceeds from the offering principally for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities.
  • The Company intends to use the net proceeds from this offering to fund the clinical development of KB103 and KB105, the preclinical development of its other pipeline candidates, manufacturing and for working capital and other general corporate purposes.
  • PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary diseases.
  • gene intends to use the net proceeds from this offering to fund research and development of its product candidates and development programs, including its ongoing and planned clinical trials of UCART19, ALLO-501 and ALLO-715, as well as the expansion of its manufacturing facilities and for working capital and other general corporate purposes.
  • The Company expects to use the proceeds from this offering for the development of treatments and to expand their pipeline of product candidates through internally generated programs, licensing and acquisition opportunities, to expand internal manufacturing capabilities, to advance validation efforts and for working capital, etc.
  • Tilray intends to use the net proceeds for working capital, future acquisitions and general corporate purposes, and to repay the existing mortgage related to their facility in Nanaimo, British Columbia.
  • Orchard Therapeutics Limited is a commercial-stage, fully-integrated biopharmaceutical company dedicated to transforming the lives of patients with fatal rare diseases through autologous ex vivo lentiviral gene therapies.
1 2 3 4 ...85 Next